JP2005516606A - 哺乳動物のサイトカイン;関連する試薬の使用 - Google Patents

哺乳動物のサイトカイン;関連する試薬の使用 Download PDF

Info

Publication number
JP2005516606A
JP2005516606A JP2003565411A JP2003565411A JP2005516606A JP 2005516606 A JP2005516606 A JP 2005516606A JP 2003565411 A JP2003565411 A JP 2003565411A JP 2003565411 A JP2003565411 A JP 2003565411A JP 2005516606 A JP2005516606 A JP 2005516606A
Authority
JP
Japan
Prior art keywords
tslp
cells
seq
cell
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003565411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516606A5 (cg-RX-API-DMAC7.html
Inventor
ウォル マルフィ, レン デ
ヨン−ジュン リウ,
マレハリ エル. ナガラクシュミ,
バジル ソウムリ,
ノリヒコ ワタナベ,
ウェイ ユアン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27734298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2005516606(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2005516606A publication Critical patent/JP2005516606A/ja
Publication of JP2005516606A5 publication Critical patent/JP2005516606A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2003565411A 2002-02-01 2003-01-30 哺乳動物のサイトカイン;関連する試薬の使用 Pending JP2005516606A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35350902P 2002-02-01 2002-02-01
PCT/US2003/002758 WO2003065985A2 (en) 2002-02-01 2003-01-30 Uses of mammalian cytokine; related reagents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009060287A Division JP5519946B2 (ja) 2002-02-01 2009-03-12 哺乳動物のサイトカイン;関連する試薬の使用

Publications (2)

Publication Number Publication Date
JP2005516606A true JP2005516606A (ja) 2005-06-09
JP2005516606A5 JP2005516606A5 (cg-RX-API-DMAC7.html) 2006-03-02

Family

ID=27734298

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003565411A Pending JP2005516606A (ja) 2002-02-01 2003-01-30 哺乳動物のサイトカイン;関連する試薬の使用
JP2009060287A Expired - Lifetime JP5519946B2 (ja) 2002-02-01 2009-03-12 哺乳動物のサイトカイン;関連する試薬の使用
JP2012138672A Pending JP2012184259A (ja) 2002-02-01 2012-06-20 哺乳動物のサイトカイン;関連する試薬の使用
JP2014103683A Pending JP2014156478A (ja) 2002-02-01 2014-05-19 哺乳動物のサイトカイン;関連する試薬の使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009060287A Expired - Lifetime JP5519946B2 (ja) 2002-02-01 2009-03-12 哺乳動物のサイトカイン;関連する試薬の使用
JP2012138672A Pending JP2012184259A (ja) 2002-02-01 2012-06-20 哺乳動物のサイトカイン;関連する試薬の使用
JP2014103683A Pending JP2014156478A (ja) 2002-02-01 2014-05-19 哺乳動物のサイトカイン;関連する試薬の使用

Country Status (11)

Country Link
US (5) US20030186875A1 (cg-RX-API-DMAC7.html)
EP (3) EP2311869B2 (cg-RX-API-DMAC7.html)
JP (4) JP2005516606A (cg-RX-API-DMAC7.html)
AU (1) AU2003208888B2 (cg-RX-API-DMAC7.html)
CA (1) CA2474011C (cg-RX-API-DMAC7.html)
DK (1) DK2311869T3 (cg-RX-API-DMAC7.html)
ES (1) ES2399503T5 (cg-RX-API-DMAC7.html)
MX (1) MXPA04007426A (cg-RX-API-DMAC7.html)
NZ (1) NZ533987A (cg-RX-API-DMAC7.html)
PT (1) PT2311869E (cg-RX-API-DMAC7.html)
WO (1) WO2003065985A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530233A (ja) * 2007-06-20 2010-09-09 アイアールエム・リミテッド・ライアビリティ・カンパニー アレルギー疾患を処置する方法および組成物
WO2012001889A1 (ja) * 2010-06-28 2012-01-05 国立大学法人東北大学 Tslpを恒常的に高発現する細胞、及び前記細胞を利用したtslp調節剤のスクリーニング方法
JP2013031441A (ja) * 2006-12-14 2013-02-14 Merck Sharp & Dohme Corp 操作された抗tslp抗体

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
CA2349762C (en) * 1998-11-13 2013-12-24 Immunex Corporation Human tslp dna and polypeptides
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
PL371773A1 (en) * 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
MXPA04007426A (es) * 2002-02-01 2004-10-11 Schering Corp Usos de citosina de mamifero; reactivos relacionados.
EP1651247B1 (en) 2003-07-18 2008-09-10 Schering Corporation Treatment and diagnosis of neoplasms using thymic stromal lymphopoietin
ES2385450T3 (es) * 2004-03-22 2012-07-25 Osiris Therapeutics, Inc. Células madre mesenquimatosas y sus utilizaciones
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
BRPI0907501B1 (pt) 2008-02-01 2021-02-23 Ceres, Inc construto de vetor, método para dirigir a transcrição, método de expressão de uma região de codificação exógena, método de alteração da expressão de um gene e método de produção de uma planta transgênica
US12331304B2 (en) 2008-02-01 2025-06-17 Ceres, Inc. Promoter, promoter control elements, and combinations, and uses thereof
EP2213682A1 (en) * 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
EP3594356A1 (en) 2009-11-04 2020-01-15 Merck Sharp & Dohme Corp. Engineered anti-tslp antibody
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
JP2012032655A (ja) * 2010-07-30 2012-02-16 Fujimori Sangyo Kk ホログラム付きラミネートフィルム及びその製造方法、これを用いた容器
JP2015502917A (ja) * 2011-10-28 2015-01-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Tslp処置のバイオマーカーとしてのil−19
EP2773774A4 (en) 2011-11-03 2015-06-10 Merck Sharp & Dohme BIOMARKERS FOR TSLP TREATMENT
EP3842457A1 (en) 2015-09-09 2021-06-30 Novartis AG Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
US6982320B2 (en) * 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
CA2343979C (en) * 1998-09-21 2011-11-15 Schering Corporation Human interleukin-b50, therapeutic uses
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
CA2349762C (en) * 1998-11-13 2013-12-24 Immunex Corporation Human tslp dna and polypeptides
US7067712B2 (en) * 2000-06-16 2006-06-27 Hitoshi Mizutani Caspase 1 gene transfer animal
EP1297017B1 (en) * 2000-06-19 2012-06-13 Beth Israel Deaconess Medical Center Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
WO2002000723A2 (en) * 2000-06-28 2002-01-03 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
MXPA04007426A (es) * 2002-02-01 2004-10-11 Schering Corp Usos de citosina de mamifero; reactivos relacionados.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013031441A (ja) * 2006-12-14 2013-02-14 Merck Sharp & Dohme Corp 操作された抗tslp抗体
JP2010530233A (ja) * 2007-06-20 2010-09-09 アイアールエム・リミテッド・ライアビリティ・カンパニー アレルギー疾患を処置する方法および組成物
WO2012001889A1 (ja) * 2010-06-28 2012-01-05 国立大学法人東北大学 Tslpを恒常的に高発現する細胞、及び前記細胞を利用したtslp調節剤のスクリーニング方法

Also Published As

Publication number Publication date
DK2311869T3 (da) 2013-03-18
EP2311869A1 (en) 2011-04-20
EP2077277A1 (en) 2009-07-08
AU2003208888A1 (en) 2003-09-02
US20100136003A1 (en) 2010-06-03
WO2003065985A3 (en) 2004-10-14
JP2009132730A (ja) 2009-06-18
WO2003065985A2 (en) 2003-08-14
JP2014156478A (ja) 2014-08-28
US20110229434A1 (en) 2011-09-22
EP2311869B1 (en) 2012-12-19
ES2399503T5 (es) 2021-04-08
US20030186875A1 (en) 2003-10-02
EP1487865A4 (en) 2005-12-14
US20070020262A1 (en) 2007-01-25
PT2311869E (pt) 2013-03-04
EP1487865A2 (en) 2004-12-22
MXPA04007426A (es) 2004-10-11
ES2399503T3 (es) 2013-04-01
CA2474011A1 (en) 2003-08-14
AU2003208888B2 (en) 2006-10-19
NZ533987A (en) 2007-04-27
JP2012184259A (ja) 2012-09-27
CA2474011C (en) 2014-03-25
EP2311869B2 (en) 2020-06-17
JP5519946B2 (ja) 2014-06-11
US20090017018A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
JP5519946B2 (ja) 哺乳動物のサイトカイン;関連する試薬の使用
Takatsu Interleukin-5 and IL-5 receptor in health and diseases
US20060039910A1 (en) Methods and compositions for treating allergic inflammation
KR20220010722A (ko) Cd4 결합 모이어티를 포함하는 면역 세포 수용체
JP2003524644A (ja) Cd40−結合性apc−活性化分子
AU2009203080B2 (en) Methods for Modulating an Inflammatory Response
KR20060052681A (ko) Gitr 리간드, gitr 리간드-연관 분자, 항체 및그의 용도
JP2009543579A (ja) 抗炎症反応のための標的としてのWSX−1/p28
KR20070107703A (ko) 인터루킨-17f 항체 및 기타 il-17f 신호전달안타고니스트 및 그의 용도
KR20080089677A (ko) Nkg2d의 조절
US20220152105A1 (en) T cell receptors and methods of use thereof
KR20210149051A (ko) T 세포 수용체 및 이의 사용 방법
JP2004526413A (ja) 可溶性il−tif/il−22レセプターまたはil−tif/il−22に結合する結合タンパク質をコードする単離された核酸分子、およびその使用
US8454955B2 (en) Methods for treating allergic airway inflammation, airway hypersensitivity, and eosinophilia
ZA200509143B (en) GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
JP2004315381A (ja) ナチュラルキラーT細胞のインターロイキン18による刺激を利用した免疫疾患治療薬剤および治療キット、並びにIgE産生の制御方法
US8246959B1 (en) Dendritic cell-associated lectin-like molecules, compositions and methods of use
Deng The contribution of IL-17A and IL-17F in the pathogenesis of antibody-induced Epidermolysis Bullosa Acquisita
Pure et al. Role of Cell Adhesion Molecules in T Cell-Myocyte Interactions in Airway Inflammation.
Kastelein et al. IL-23 Production by Cosecretion of
van Wanrooij et al. Vaccination against CD99 inhibits atherogenesis in LDL receptor deficient mice
CN1798577A (zh) 使用抗-cd52抗体诱导调节性t细胞分化和/或使调节性t细胞增殖的方法以及为此使用的药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090302

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090309

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090612